Stuttgart
21.11.25 | 07:42
14,800 Euro
-0,54 % -0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | XVIVO Perfusion AB: Interim Report January-September 2025 | 194 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2025 (Jul-Sep)Net sales amounted to SEK 189.1 million (198.5), corresponding to growth... ► Artikel lesen | |
| 13.10. | XVIVO Perfusion AB: Conference Call on Interim Report July-September 2025 | 293 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September... ► Artikel lesen | |
| 05.09. | Nomination Committee of XVIVO Perfusion AB | 240 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 28.07. | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 530 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 22.07. | Xvivo enrolls first patient in Heart Assist Transport device study | 3 | MassDevice | ||
| 21.07. | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 299 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| 11.07. | XVivo Q2 2025: Umsatzrückgang lässt Aktie einbrechen | 21 | Investing.com Deutsch | ||
| 11.07. | XVIVO Perfusion AB: Interim Report January-June 2025 | 347 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 11.07. | Marktgegenwind bremst XVIVO: Organisches Wachstum im zweiten Quartal um 11 % rückläufig | 4 | Investing.com Deutsch | ||
| 11.07. | XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds | 2 | Investing.com | ||
| 10.07. | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 364 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06. | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 315 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 334 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 418 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 303 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 416 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04. | XVIVO Perfusion AB: Annual Report 2024 | 409 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 382 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 382 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 447 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,350 | -0,58 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Eckert & Ziegler auf "Buy" mit einem Kursziel von 24 Euro belassen. Der Strahlen- und Medizintechnikkonzern habe durchwachsene Zahlen vorgelegt... ► Artikel lesen | |
| UNITEDHEALTH | 268,20 | -0,80 % | Gesundheitssektor nimmt Fahrt auf - Bayer, PanGenomic Health, UnitedHealth Group | Die schlechten Nachrichten für Google bzw. Alphabet reißen nicht ab. Die Europäische Kommission hat ein Verfahren gegen Alphabet, das Mutterunternehmen von Google, eröffnet. Ihr Vorwurf: Verstöße seitens... ► Artikel lesen | |
| INTUITIVE SURGICAL | 477,00 | -0,46 % | Where Will Intuitive Surgical Stock Be in 10 Years? | ||
| RHOEN-KLINIKUM | 12,200 | +2,52 % | Info-Film: Herzchirurgie am RHÖN-KLINIKUM Campus Bad Neustadt / Von der Anreise bis zur Entlassung | Bad Neustadt a.d. Saale (ots) - Blick hinter die Kulissen - Der neue Info-Film der Klinik für Kardiochirurgie über den Aufenthalt eines herzchirurgischen Patienten am RHÖN-KLINIKUM Campus Bad Neustadt.Eine... ► Artikel lesen | |
| HIMS & HERS HEALTH | 28,790 | -1,34 % | HeraMED startet durch: US-Topmanagerin neu im Vorstand - und Garmin als Technologiepartner! | ||
| BICO GROUP | 1,647 | +0,12 % | BICO Group AB: Publication of BICO Group AB: Interim report Q3 2025 | Organic sales growth in a continued soft market
Q3 2025 SummaryLife Science Solutions showed 4 percent organic sales growth YoY, which is in line with market performance. SCIENION continued to perform... ► Artikel lesen | |
| M1 KLINIKEN | 15,920 | -3,05 % | EQS-News: M1 Kliniken AG verzeichnet starkes EBIT-Wachstum von 11% und erzielt Ergebnis je Aktie von 0,86EUR. | EQS-News: M1 Kliniken AG
/ Schlagwort(e): 9-Monatszahlen/Quartalsergebnis
M1 Kliniken AG verzeichnet starkes EBIT-Wachstum von 11% und erzielt Ergebnis je Aktie von 0,86EUR.
18.11.2025... ► Artikel lesen | |
| BAXTER | 15,102 | -0,05 % | BAXTER INTERNATIONAL INC - 8-K, Current Report | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 6,900 | -6,76 % | M Stanley Lifts JD HEALTH TP to $68.8, Keeps Rating at Equalweight | ||
| LIFEWARD | 0,523 | 0,00 % | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27%... ► Artikel lesen | |
| COOPER COMPANIES | 63,50 | +2,42 % | Browning West pushes Cooper Cos. board to appoint its directors | ||
| SURGICAL SCIENCE SWEDEN | 6,600 | +3,45 % | Surgical Science Sweden AB: Interim report January-September 2025: Progress in the right direction | Third quarter 2025 (July - September)Net sales amounted to SEK 263.6 (231.8) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,040 | +10,87 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results | Updated interim results from the Company's [212Pb]VMT-a-NET Phase 1/2a study supporting the therapy's compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 38,200 | -8,39 % | Wolfe Research initiates Soleno Therapeutics stock with Outperform rating |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,080 (-0,54 %) liegt der Kurs bei 14,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.